El trading conlleva riesgos
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Imunon Inc
Cerrado
0.55 1.85
Resumen
Variación precio
24h
Mínimo
0.4
Máximo
0.59
Empleados | 25 |
|---|
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +2757.14% upside |
Próximas Ganancias | 13 ago 2025 |
|---|
Capitalización Mercado | -245K 11M |
|---|---|
Apertura anterior | -1.3 |
Cierre anterior | 0.55 |
Imunon Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Imunon Inc previsión
Precio Objetivo
By TipRanks
2757.14% repunte
Estimación a 12 Meses
Media 14 USD 2757.14%
Máximo 14 USD
Mínimo 14 USD
De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Imunon Inc Dist en los últimos 3 meses.
Finanzas
$
Acerca de Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
